Great progress has been made in the treatment of patients with advanced non-small cell lung cancer (NSCLC) and colorectal cancer over the past few years. However, the therapy options are limited if the condition continues to advance despite chemotherapy and drug immunotherapy. For patients with advanced soft tissue sarcoma (STS), the options are still limited to chemotherapy.
The IP-IIO-622_SAKK 69/22 trial will investigate a treatment approach for when immunotherapy and chemotherapy are no longer effective: the thermal ablation of a tumor followed by injection of the trial medication IP-001 directly into the pre-treated tumor.
Previous trials have shown that the combination of the trial product and thermal ablation may help the immune system (the body's defense system) be effective against cancer and destroy the remaining cancer cells (located some distance away from the tumor) in the body.
The main aim of the trial is to establish how safe the trial medication is and how well it is tolerated following thermal ablation. The trial will also examine
Blood and tumor tissue samples will therefore be taken and analyzed in more detail during the course of the trial to better understand the immune response and the mechanism of action of the therapy.